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Abstract: Omeprazole (OME) is employed for treating ulcer in children, but is unstable and exhibits
first pass metabolism via the oral route. This study aimed to stabilize OME within mucoadhesive
metolose (MET) films by combining cyclodextrins (CD) and L-arginine (L-arg) as stabilizing excipients
and functionally characterizing for potential delivery via the buccal mucosa of paediatric patients.
Polymeric solutions at a concentration of 1% w/w were obtained by dispersing the required weight of
metolose in 20% v/v ethanol as solvent at a temperature of 40 ◦C using polyethylene glycol (PEG 400)
(0.5% w/w) as plasticizer. The films were obtained by drying the resulting polymer solutions at in an
oven at 40 ◦C. Textural (tensile and mucoadhesion) properties, physical form (differential scanning
calorimetry (DSC), X-ray diffraction (XRD) and Fourier transform infrared (FTIR) spectroscopy),
residual moisture content (thermogravimetric analysis (TGA)) and surface morphology (scanning
electron microscopy (SEM)) were investigated. Optimized formulations containing OME, CDs (β or
γ) and L-arg (1:1:1) were selected to investigate the stabilization of the drug. The DSC, XRD, and
FTIR showed possible molecular dispersion of OME in metolose film matrix. Plasticized MET films
containing OME:βCD:L-arg 1:1:1 were optimum in terms of transparency and ease of handling and
therefore further functionally characterized (hydration, mucoadhesion, in vitro drug dissolution
and long term stability studies). The optimized formulation showed sustained drug release that
was modelled by Korsmeyer–Peppas equation, while the OME showed stability under ambient
temperature conditions for 28 days. The optimized OME loaded MET films stabilized with βCD
and L-arg have potential for use as paediatric mucoadhesive buccal delivery system, which avoids
degradation in the stomach acid as well as first pass metabolism in the liver.
Keywords: buccal mucosa drug delivery; cyclodextrins; films; L-arginine; mucoadhesive polymer;
omeprazole; paediatric
1. Introduction
Gastro-oesophageal reflux involves movement of excessive acid from the stomach into the
oesophagus. It affects a significant number of infants, exhibiting an array of symptoms, including
physiological reflux, hematemesis, or even sudden infant death syndrome. Many of these children
suffer from gastro-oesophageal reflux but with no definite causes or accompanying complications [1].
In addition, some investigations that assessed the effects of early therapeutic interventions showed
that about 55% of the infants are free of any clinical symptoms by the time they are 10 months old
and this increases to 81% by 18 months old [2]. That notwithstanding, it is still vital to identify which
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children exhibit gastro-oesophageal reflux-associated disease to allow selection of the most effective
therapy for treating the manifestations of the disease [3].
Until recently, Cisapride which possesses 5HT-4 antagonist characteristics, was the drug of choice
in gastro-oesophageal reflux [4]. However, due to cardiac dysrhythmias associated with its use,
Cisapride is no more routinely prescribed for the condition. Although histamine receptor 2 antagonists
(H2RAs) can provide relief from oesophagitis, and high-dosage ranitidine (20 mg·kg−1·day−1)
demonstrated as effective in refractory reflux oesophagitis, side effects such as nocturnal acid
secretion present a limitation [5]. It has been shown that pharmacological tolerance of proton pumps
inhibitors (PPIs) is good, safe for patients and an effective way of treating gastro-oesophageal reflux
disease (GERD) [6]. PPIs are chemical compounds that inhibit hydrogen/potassium adenosine
triphosphatase enzymes in the stomach wall, and providing relief from oesophageal, gastric and
duodenal ulcers as well as from GERD [5]. They act by changing their chemical structure upon
interaction with H+/K+ adenosine triphosphatase enzyme in the parietal cells, which leads to the
formation of its active derivative through acceptance of a H+ proton, thereby increasing stomach
pH whilst reducing the secretion of acid from the stomach wall. Furthermore, the protonated
derivative can bind with parietal cells in the stomach wall, and subsequently lowers the secretion
of acid even further [7]. PPIs can be divided into: (i) competitive; and (ii) covalent, with the
competitive PPIs exerting reversible inhibition of the proton pump mechanism in the wall of the
stomach by binding to its extracellular surface. On the other hand, PPIs belonging to the covalent
class cause inhibition, which is not reversible, and results in a longer period for the secretion
of other enzymes. Initially, 2-methyl-8-(phenyl-methoxy)-imidazo-1,2-pyridin-3-acetonitrile and
3-butyryl-8-methoxy-4-(2-tolylamino) quinolone were the most common PPIs, however, more recent
groups are composed mainly of benzimidazole derivatives such as omeprazole and pantoprazole [8].
Omeprazole (OME) is an effective therapy for treating ulcers of the stomach and duodenum often
combined with antibacterial drugs to eliminate Helicobacter pylori [9]. For children suffering from
GERD and demonstrating acute symptoms as well as those with erosive, ulcerative, or stricturing
(narrowing) of the oesophagus caused by using endoscopy, a starting course of OME is the therapeutic
regimen of choice [10]. OME is also used to prevent and treat ulcers resulting from using non-steroidal
anti-inflammatory drugs (NSAID), and the dose of OME should normally be maintained in such
situations even after healing of the ulcer to avoid chances of recurring [11]. Furthermore, OME is
effective for treating Zollinger–Ellison syndrome and also employed to aid in reducing degradation of
pancreatic enzyme supplements in children suffering from cystic fibrosis [8].
However, although OME is effectively absorbed from the gastrointestinal tract, the systemic
bioavailability after oral administration is between 40% and 50% which suggests that the drug
experiences significant first pass metabolism in the liver. Once it is absorbed, OME gets metabolized
into three main metabolites: OME sulphone, OME sulphide and hydroxyl OME, all of which have
been detected in human plasma [12]. Hydroxylation position 5 is subject to genetic polymorphism and
the sulphone in plasma is accumulated in patients who metabolize S-mephenytion 4′ hydroxylation
poorly [13]. Another challenge with the drug is that, in aqueous solution, OME’s stability is solely
determined by the pH and rapidly degrades under acidic and neutral conditions, but shows better
stability in alkaline environments [14]. OME is also rapidly degraded by heat, light and humidity [15].
These limitations present a formulation challenge in the design and manufacture of oral pharmaceutical
delivery systems with optimum bioavailability due to its rapid gastric degradation [9]. To avoid such
stomach acid breakdown, OME is formulated as enteric-coated granules in the form of capsules [2]. As
a result, alternative formulations for administration via non-enteric routes such as buccal mucosa have
been proposed [16,17]. These notwithstanding, the physical instability of OME remains an issue during
formulation and storage and therefore requires stabilizing agents such as L-arginine and cyclodextrins.
Cyclodextrins (CDs) are oligosaccharides with cyclic configurations employed as excipients
in different fields such as the preparation of inclusion complexes utilized in various dosage forms.
They are able to form water-soluble complexes with poorly water soluble drugs which fit into their
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cavities [18]. The three main types of CDs are α, β and γ comprising 6, 7 and 8 D-glucose units
respectively. The molecular structure of CDs involves glucopyranose units in 4C1-chair conformation
connected through α (1→ 4) bonds. The glucose units are syn-oriented in which O-6 hydroxyls are on
one side of the ring while the O-2 and O-3 hydroxyls are on the other side. The internal hydrophobic
cavity of CDs facilitates their formation of inclusive complexes which allows their effective use as a
drug carrier to improve drug solubility, chemical stability, dissolution and bioavailability or to decrease
unfavourable side effects.
L-arginine (S-2-amino-5-guanidinopentanoic acid) is an amino acid which is basic in nature and
presents naturally in human diets, especially foods such as meats and nuts. Arginine prevents the
involution of thymic after surgery and helping in the increase of lymphocytes which is an essential
agent for adequate wound healing. In addition, arginine is used as an auxiliary substance to increase
the water molecular solubility of other compounds [19].
Metolose (MET) is a non-ionic water-soluble cellulose ether that is derived from pulp. Highly
purified pulp is etherified with methyl chloride or a combination of methyl chloride and propylene
oxide to form a water soluble, non-ionic cellulose ether. It can produce transparent films by casting from
their gel solutions [20] and the film properties markedly depend on the moisture content [21]. MET
comprises methylcellulose and three substitution types of hydroxypropylmethylcellulose (HPMC) each
available in several grades (SM, SH and SE) with varying viscosities based on the type of esterification
agent. The SM type is rich in methyl groups, SH type is rich in both hydroxypropyl and methyl groups
while the SE type is rich in hydroxyethyl and methyl groups [22]. Some of the key properties of MET
include solubility in cold water and forms transparent solutions; it forms reversible gels during heating
due to its viscoelastic properties and the formed gel maintains its shape during heating [23,24].
In this study, we report on the stabilizing effects of βCD and γCD combined with L-arg for OME
in polymer (MET) based mucoadhesive buccal films for potential delivery to paediatric patients. In
addition, the films were functionally characterized for swelling, adhesiveness, dissolution of OME,
its release kinetics and long-term stability over 28 days (four weeks). The originality of the research
presented in this paper is the use of a composite stabilizing system combining CDs and L-arg within
a polymer based mucoadhesive buccal formulation, which overcomes limitations of current oral
gastrointestinal delivery.
2. Materials and Methods
The mucoadhesive polymer, Metolose (MET) was provided as a gift by Shin Etsu (Stevenage,
Hertfordshire, UK). Polyethylene glycol (PEG 400), L-arginine (L-arg), gelatin and beta cyclodextrin
(βCD) were purchased from Sigma-Aldrich (Gillingham, UK), ethanol, potassium dihydrogen
phosphate and sodium hydroxide from Fisher Scientific (Leicester, UK) whilst omeprazole (OME) and
gamma cyclodextrin (γCD) were purchased from TCI (Tokyo, Japan).
2.1. Formulation (Gel and Film) Development
Solvent cast films were formulated from ethanolic gels of the mucoadhesive polymer (MET)
and loaded with drug (OME) as previously reported [17]. Briefly, the OME was dissolved in 20%
v/v EtOH together with βCD or γCD at different ratios to form an OME solution as summarized in
Table 1a. Subsequently, MET powder was slowly added to the vigorously stirred drug–CD solution
at room temperature to obtain the drug loaded (DL) CD gels. The gels obtained gels were covered
using parafilm, left to stand to allow the escape of air bubbles after which 20 g was poured into Petri
dishes and left to dry in an oven set to a temperature of 40 ◦C [25]. Further, due to visually observed
degradation of the drug even in the presence of either βCD or γCD alone in the ethanolic gel, L-arg
was added in the CD containing gels as shown in Table 1b. During this step, L-arg (0.10% w/w) was
incorporated into the gel whilst maintaining the concentration of the original OME (0.10% w/w), βCD
(0.10% w/w), and γCD (0.10% w/w) constant [26].
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Table 1. (a) Composition of omeprazole (OME) loaded metolose (MET) ethanolic gels containing
varying concentrations of amounts of beta cyclodextrin (βCD) and gamma cyclodextrin (γCD),
polyethylene glycol 400 (PEG 400) at a concentration of 0.50% w/w; and (b) optimized gels containing
0.50% w/w PEG 400, βCD and γCD as well as L-arginine (L-arg) in ratio of OME:CD:L-arg 1:1:1.




PEG 400 0.5 0.5
βCD 0.1 0.2 0.3 0.1




A texture analyser (HD plus, Stable Micro System, Surrey, UK) equipped with a 5 kg load cell
and texture exponent-32 software program was employed. Thickness and width of the films were
measured and entered into the software program and used to calculate the tensile parameters. The
films free from any physical defects, with the average thickness of (0.07 ± 0.01 mm) were selected for
testing. The films which were cut in the shape of dumb-bell strips were attached to two tensile grips
which were 30 mm apart and stretched at the speed of 1.0 mm/s till they broke. The tensile strength
(representing film brittleness), elastic modulus (rigidity) and percentage elongation (flexibility and
elasticity) were calculated using Equations (1)–(3). Each experiment was undertaken three times (n = 3)
and average values calculated.
Tensile strength =
Force at f ailure
cross− sectional area o f the f ilm (1)
Percent elongation at break =
Increase in length at break
Initial f ilm length
× 100 (2)
Young′s modulus = slope o f stres− strain curve
Film thickness × Cross head speed (3)
2.2.2. Thermal Analysis
Hot Stage Microscopy (HSM)
These experiments were performed using a Mettler Toledo FP82HT (Greifensee, Switzerland)
with a Nikon Microphot. Optimized MET DL films plasticized with 0.5% PEG 400, and containing
OME:L-arg:βCD in ratio of 1:1:1 were placed on a glass slide, covered with a coverslip, and heated
from ambient temperature to 200 ◦C at a rate of 10 ◦C/min. The changes in morphological behaviour
with heating were collected in the form of a video recording with the help of a PixeLINK PL-A662
camera (PixeLINK, Ottawa, ON, Canada).
Differential Scanning Calorimetry (DSC)
DSC was performed for MET DL films analysed for HSM above and changes in their properties
after the addition of PEG and OME within the films investigated. Small strips of each film (DL
OME:L-arg:βCD 1:1:1), and starting materials (MET, OME and L-arg) weighing about 2.5 mg, were
placed into hermetically sealed Tzero aluminium pans with a pin hole in the lid. The pans containing
the samples were then heated in a Q2000 (TA Instruments, New Castle, DE, USA) calorimeter from a
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low temperature of 40 ◦C to 180 ◦C using a heating rate of 10 ◦C/min under constant flow of nitrogen
(N2) (100 mL/min) to evaluate the glass transition, melting point, crystallization and a possible
interactions between polymer and plasticizer [27].
Thermogravimetric Analysis (TGA)
TGA analyses were performed with the help of a Q5000 (TA Instruments, New Castle, DE, USA)
thermogravimetric analyser to investigate the amounts of residual moisture within the films. About
1–2.5 mg (n = 3) of the optimized DL films (films prepared from ethanolic gels plasticized with 0.5%
PEG 400, and containing OME:L-arg:βCD 1:1:1) were placed into hermetically sealed Tzero aluminium
pans. The films were then heated from ambient temperature (20 ◦C) to 200 ◦C at a rate of 10 ◦C/min
under nitrogen (N2) gas at a gas flow rate of 25 mL/min, to evaluate the residual moisture content of
the starting materials (MET, OME, CD, L-arg) and DL films.
2.2.3. Scanning Electron Microscopy (SEM)
The surface morphology, general uniformity and the presence of any cracks in the optimized
MET DL films were investigated with SEM. Films were mounted onto Agar Scientific G301 aluminium
pin-type stubs (12 mm diameter) with Agar Scientific G3347N double-sided adhesive carbon tapes and
coated with chromium (Sputter Coater S150B, 15 nm thickness). The coated films were then evaluated
using a Hitachi Triple detector CFE-SEM SU8030, (Hitachi High-Technologies, Tokyo, Japan) scanning
electron microscope at an accelerating voltage of 2 kV [28,29].
2.2.4. X-ray Diffraction (XRD)
XRD was used to analyse the physical form (crystalline or amorphous) of the optimized MET
DL films. XRD diffractograms were obtained on a DIFFRAC plus instrument (Bruker, Coventry,
UK) equipped with an XRD commander program. A Goebel mirror was used to produce a focused
monochromatic CuKα1&2 primary beam (λ = 1.54184 Å) with exit slits of 0.6 mm and a Lynx eye
detector and voltage and current settings set at 40 kV and 40 mA, respectively. The samples for analysis
were prepared by cutting the films into 2 cm2 square strips to fit the square tiles of the holder. The
films were subsequently mounted on the sample cell and then scanned between 2 theta of 0◦ to 70◦
with 0.1 s step size [30,31].
2.2.5. Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) Spectroscopy
FTIR spectra were obtained using a Perkin Elmer spectrophotometer (Spectrum Two, Perkin
Elmer, San Diego, CA, USA) equipped with a crystal diamond universal ATR sampling accessory
(UATR). Prior to the start of each sample measurement, the ATR crystal was cleaned thoroughly using
tissue paper soaked in ethanol. During the measurement, the films made intimate contact with the
universal diamond ATR top-plate, enabled by a pressure clamp to hold samples in place throughout
the analysis. For each sample, the spectra representing an average of 4 scans were recorded in the
range of 4000–400 cm−1.
2.3. Functional Characterization
Functional characteristics were investigated for the selected optimized MET DL films (0.5% PEG
400, OME:L-arg:βCD 1:1:1).
2.3.1. Swelling Index (Capacity)
The swelling capacities of the films were determined by incubating the samples in 0.01 M PBS
solution at a pH of 6.8 ± 0.1 (to simulate salivary pH) and heated to a temperature of 37 ± 0.1 ◦C. The
films were cut into 2 × 2 cm square strips and placed into Petri-dish containing 10 mL of the hydrating
solution (PBS) and initially weighed. At predetermined time intervals (5 min), the PBS solution was
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completely removed using a syringe and weighed again. Before the films were weighed, excess PBS
solution was gently off blotted using paper towels. After weighing, 10 mL of fresh PBS solution
maintained at a temperature of 37 ± 0.1 ◦C was placed back in the Petri dish using a syringe. The
experiments were performed in triplicate (n = 3) for each set of formulated samples and the percentage





where Ws is the initial weight of the film before hydration and Wi is the initial weight of the film after
hydration in the PBS solution.
2.3.2. In Vitro Mucoadhesion
The in vitro mucoadhesion experiments were performed using the TA HD plus Texture Analyzer
(Stable Micro Systems, Surrey, UK) fitted with a 5 kg load cell. The film was attached to an adhesive
rig probe having a diameter of 75 mm using double sided adhesive tape. A model mucosal substrate
was prepared by first dissolving 6.67 g of gelatin in 100 mL of warm deionized water and pouring
20 g of the warm solution into Petri dishes with diameter of 88 mm diameter and allowed to set as a
solid gel. To allow proper simulation of the oral buccal mucosa and the surface of the set gelatin gel
was equilibrated with 0.5 mL PBS (pH 6.8) to represent the buccal mucosa [32]. The film was attached
to the texture analyser probe and placed in contact with the equilibrated gelatin gel for a period
of 60 s to provide optimal contact and hydration. The following settings: pre-test speed 0.5 mm/s;
test speed 0.5 mm/s; post-test speed 1.0 mm/s; applied force 1 N; trigger type auto; trigger force
0.05 N and return distance of 10.0 mm, in tension mode were used during the measurements and
Texture Exponent 32 software was used to record and process the data. The peak adhesive force (PAF)
required to completely detach the film from the gelatin surface was determined by the maximum force,
area under the curve (AUC) representing the total work of adhesion (TWA) was estimated from the
force-distance plot and the cohesiveness of the sample was determined by the distance travelled by
the film before complete detachment.
2.3.3. In Vitro Release of Omeprazole (OME) Using Franz-Type Diffusion Cell
Prior to investigating the drug release and dissolution profiles, drug assay and uniformity of
OME within the film was determined. This was determined by first weighing the film accurately to a
weight of 5 mg (n = 3) and hydrating in 8 mL of 0.01 M PBS solution at a pH of 6.8 and stirred at a
temperature of 37 ± 0.5 ◦C until completely dissolved. The concentration of OME was analysed using
HPLC (as described below).
For the in vitro drug dissolution studies, a Franz-type diffusion cell was used comprising donor
compartment and receiver compartment. Five milligrams of the optimized MET DL film were placed
in the donor compartment on stainless steel wire mesh (0.5 mm × 0.5 mm) which separated the
donor and receiver compartments, with the mucoadhesive surface in contact with the wire mesh
and facing the receiver compartment of the Franz diffusion cell [33]. The receiver chamber was filled
with 8 mL of 0.01 M PBS pH 6.8, 37 ◦C and magnetically stirred at a speed of 250 rev/min. The
chambers were held together with the help of a cell clamp and also sealed with parafilm to reduce
evaporation. At predetermined time intervals, aliquots (1 mL) of the PBS medium was sampled and
replaced with the same amount of fresh solution to keep the total volume constant over a 2 h period.
The sampled dissolution medium was first filtered into an HPLC sample vial and analysed at 302 nm
using HPLC (see Section 2.2.4). The concentration of OME released from the film was determined from
the linearized calibration curve (R2 > 0.99) and percentage cumulative drug release profiles plotted.
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2.4. Drug Stability
Drug stability within the optimized films was determined by analysing the amount of drug
present in the films after storing under two sets of conditions. Samples were placed in humidity
controlled desiccators and placed in ovens at 40 ◦C representing accelerated conditions and the other
at room temperature (ambient) over a period of 4 weeks. The MET DL film (OME:βCD:L-arg 1:1:1,
PEG 400 (0.5% w/w) was placed in the desiccators and wrapped with aluminium foil due to its light
sensitivity and to prevent moisture absorption by MET. For HPLC analysis, the stored samples were
accurately weighed (5 mg) and hydrated in 0.01 M PBS solution (pH 6.8 ± 0.1 simulating salivary pH)
in volumetric flasks (10 mL) and left to completely dissolve. Aliquots (1 mL) of the sample solution
from each flask was removed and filtered into HPLC vials prior to analysis by HPLC.
An Agilent 1200 HPLC machine equipped with auto sampler (Agilent Technology, Cheshire,
UK) with Chemstation® software program was used to analyse the samples. A Hypersil™ reversed
phase ODS C18 HPLC column, with particle size of 5 µm and respective length and diameter of
250 mm × 4.6 mm (Thermo Scientific, Hampshire, UK), was used as the stationary phase. The mobile
phase was prepared by mixing ammonium acetate and acetonitrile in the ratio of 60:40 v/v. The flow
rate of the mobile phase was maintained at 2 mL/min and diode array UV detector wavelength for
OME was set at 302 nm; with injection volume of 20 µL during each run.
3. Results and Discussion
3.1. Formulation Development and Optimization
The polymer (MET), which is a combination of hydroxypropylmethylcellulose and methyl
cellulose, used in this study, was chosen because of its hydrophilic nature and well known swelling and
mucoadhesive properties [34,35]. Stirring was applied during gel formulation to prevent formation
of lumps which could occur through incomplete hydration, whilst heating the resulting mixture to a
temperature of 40 ◦C reduced the viscosity of the final gels and helped air bubbles generated during
stirring, to escape easily to the surface and subsequently released into the surrounding atmosphere.
Furthermore, the reduced viscosity also allowed ease of pouring of the gels into the casting Petri
dishes [36]. In addition, aqueous ethanolic solution (20% v/v of ethanol in water) was used as solvent
because both OME and MET were more easily dissolved than water alone whilst also helping to reduce
the drying time due to its volatility.
Physical Evaluation of DL Films
One of the major challenges with OME is its physical and chemical instability, and therefore a
key objective of this study was to stabilize the drug within the MET films using CDs either alone
or in combination with L-arg. When OME is added to water, it dissolves quickly to produce a clear
solution. OME dissolves very rapidly in the presence of water to yield a clear solution, and its stability
after addition of MET and PEG, plays an important role in the overall stability of the final DL gel and
subsequently the film formulation [37]. However, it was observed that the drug quickly showed signs
of degradation within 20 min with the colour of the gel changing to red. This is because OME is only
stable in alkaline solutions above pH 6.5.
The stabilization of OME was attempted by introducing two different types of CDs (β and γ) into
the DL gel in three different ratios as shown in Table 1a,b. Although the OME loaded gels remained
stable over a longer period (hours) in the presence of βCD and γCD, the colour of the gel eventually
changed to brownish-red suggesting that both CDs on their own could not sustain the stability of
the drug during gel and film formulation. The visual observations made for the final appearance of
the different films were captured with a digital camera as shown in Figure 1. On the contrary, the
OME-CD complex within the gels and the final dried films was stabilized in the presence of L-arg as
shown in Figure 2, clearly depicting desirable and optimum properties of homogeneity, transparency
and uniform drug distribution. This is because OME is unstable at low pH but this improves at higher
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pH and the presence of L-arg provides a neutral to weakly alkaline environment which improved
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The molecular mechanism of how L-arg and OME interact with βCD by the formation of inclusion
complexes, has been reported in the literature based on the work by Figuerias and co-workers [38].
They showed that with the presence of L-arg, the difference observed in the mean distances between
the “e” and “f” atoms of OME to the centre of mass of CD’s O4 atoms, which was considered as a
reference to the centre of the CD inner cavity of the two complexes, was not significant [38]. They
further suggested that for OME:L-arg combined in equal ratios, the H atom of the L-arg was nearer
in proximity to the nitrogen atom of OME and noted that the distance between the H (L-arg) and the
N (OME) was relatively small, and explained that this increased the probability of hydrogen bonds
forming between the two compounds. The visual characterization for the physical appearance of
the films based on the most ideal characteristics (transparency, ease of peeling and flexibility) are
summarized in Table 2. In summary, based on the visual evaluation, it was determined that DL MET
films combining either L-arg and βCD or L-arg and γCD in the ratio of OME:CD:L-arg 1:1:1 were most
optimum and were therefore selected for further analytical and functional characterization studies.
Table 2. Ideal characteristics of optimized drug loaded (DL) films of βCD and γCD.
Polymer Solvent PEG (%w/w) OME (g) βCD (g) L-arg (g) Ease of Peeling Film Characteristics
MET 20% EtOH 0.5 0.1 0.1 0.1 YES Transparent/flexible
Polymer Solvent PEG (%w/w) OME (g) γCD (g) L-arg (g) Ease of Peeling Film Characteristics
MET 20% EtOH 0.5 0.1 0.1 0.1 YES Transparent/flexible
3.2. Physico-Chemical Characterization
3.2.1. Texture Analysis (TA)
Texture analysis was used to characterize the tensile behaviour of the films by measuring tensile
strength, elastic modulus and per cent elongation at break of the DL films. The tensile properties were
used to evaluate the effects of OME, βCD, γCD and L-arg on the behaviour of the plasticized MET
films and the results used to further select the most appropriate formulations for further analysis. The
effects of CD on the tensile strength values of the films are shown in Figure 3 and showed significant
differences (p < 0.05) in the tensile strength (brittleness).
It has been reported that, ideally, the mean per cent elongation at break for thin films should fall
somewhere between values of 30 to 60% [36] which is indicative of an appropriate balance between
flexibility and elasticity. The βCD loaded film satisfied this required criterion, however, γCD loaded
films gave a low per cent elongation at break as shown in Figure 3. Based on the previously identified
ideal characteristics for a good film in terms of flexibility, uniformity and transparency, the formulations
prepared from ethanolic gels containing 1:1:1 ratio of OME:βCD:L-arg and plasticised with 0.5% w/w
PEG400 was confirmed to be the most appropriate for further investigations.
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could be heated. For the selected βCD containing films, the results showed that with increase in 
temperature, the surface of the film changed from rough to clear as a result of water evaporation from 
the film matrix as shown below in Figure 4. It has been reported in the literature [39] that βCD 
undergoes a melt transition between 290 °C and 300 °C. However, Figure 4 shows melting after 260 
°C, followed immediately by decomposition. 
fi t l l c t i i (0. : -arg ( : : )
- SD, (n = 3)).
3.2.2. Ther al nalysis
results were used to aid the dev lopment of appro iate heating cycles during the TGA
and DSC analyses and helped to determine the maximum te perature to which the samples could be
heated. For th selected βCD ontaining films, the results s ow d that with incre se in temp rature,
he su face of the film chang d from rough t clear as a result of water evaporation from the fil
matr x as shown below i Figure 4. It has been reported in the li rature [39] th βCD undergoes a
melt transition between 290 ◦C and 300 ◦C. However, Figure 4 shows melting after 260 ◦C, followed
immediat ly by d composition.
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Differential Scanning Calorimetry (DSC)
DSC was employed to investigate the interactions between the components (MET, PEG 400, L-arg
and model drug (OME)) of the formulation within the film matrix as shown in Figure 5a. The polymer
(MET) showed a broad endothermic peak between 60–80 ◦C, caused by evaporation of water and no
definite melt or glass transition peak, whilst pure OME showed a melting peak at 158 ◦C and L-arg at
100 ◦C, with pure βCD showing broad endothermic peak at 60.1 ◦C attributed to water loss with no
definite melt or glass transition peaks (Figure 5b). The thermograms (Figure 5c) of plasticized MET DL
films loaded with OME:βCD:L-arg in equal proportions, exhibited a broad endothermic transition with
peak temperature of 62 ◦C and no melt peaks for OME and L-arg, suggesting films were amorphous.
However, SEM and XRD analyses were further undertaken to confirm this definitively.
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3.2.3. Scanning Electron Microscopy (SEM) 
The morphology and topographic appearance of DL MET films containing drug (OME) and 
stabilizers (L-arg and βCD) were analysed with the help of SEM, as shown in Figure 6. The results 
show that pure βCD appeared as irregular particles without any well-defined shapes. 
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Figure 5. Differential scanning calorimetry (DSC) thermograms for: (a) the pure metolose (MET),
pure omeprazole (OME), pure L-arginine (L-arg) and polyethylene glycol (PEG 400); (b) pure beta
cyclodextrin (βCD); and (c) plasticized drug loaded (DL) MET films from gels loaded with 0.5% w/w
PEG 400 and containing OME:βCD:L-arg (1:1:1).
Thermogravimetric Analysis (TGA)
TGA was employed to quantify the residu l water content as a percentage of the total film eight.
The water content for βCD after heating from ambient temperature (20 ◦C) to 100 ◦C was 13.09%
whilst the MET DL films containing OME:βCD:L-arg (1:1:1) had a residual water content of 4.04%. The
residual water was significantly lower for films compared to the pure βCD which is due to EtOH in
the gels which increased the rate of water evaporation during drying to obtain the films coupled with
the oven drying temperature of 40 ◦C. Such low residual moisture is expected to contribute towards
the slower rate of OME degradation by hydrolysis, which is important given the known poor stability
of OME.
3.2.3. Scanning Electron Microscopy (SEM)
The morphology and topogr phic appe ance of DL MET films containing drug (OME) and
stabilizers (L-arg and βCD) were analysed with the help of SEM, as shown in Figure 6. The results
show that pure βCD appeared as irregular particles without any well-defined shapes.
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Figure 6. Scanning electron microscopy (SEM) micrograph of: (a) pure beta cyclodextrin (βCD); and (b)
plasticized drug loaded (DL) metolose (MET) films cast from ethanolic (20% v/v EtOH) gels containing
0.5% w/w PEG 400 and OME:βCD:L-arg (1:1:1).
T e topography of the plasticized films containing OME:βCD:L-arg (1:1:1) showed continuous
sheets with relatively smooth and homogeneous surfaces and no pores observed. This suggests that
all formulation constituents were uniformly mixed during gel and film formation. However, small
structures with circular shapes can be seen on the film surface and could be attributed to excess OME
or βCD precipitating out due to the rapid evaporation of ethanol and water during drying and film
formation, but this requires further evaluation.
3.2.4. X-ray Diffraction (XRD)
XRD analysis was perfor ed to investigate the estimated crystalline–amorphous ratio and confirm
the physical form of the various components of the films. The XRD diffractograms of the pure βCD
and DL MET films cast from ethanolic gels (20% v/v EtOH) gels containing OME:βCD:L-arg (1:1:1)
with 0.5% w/w PEG 400 are shown in Figure 7.
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The results show that pure βCD was crystalline and confirmed the DSC results. In addition, small
additional peaks corresponding to pure OME and βCD were observed, which indicate small levels of
crystallinity within the plasticized film, however, overall, the films were generally amorphous. The
crystalline:amorphous ratio was estimated at 2% which suggests there could be small amounts of free
OME and/or βCD present in these films and could be attributed to the small amounts of recrystallized
structures present on the film surface according to the SEM images.
3.2.5. Fourier Transform Infrared (FTIR) Spectroscopy
FTIR analysis was employed to investigate molecular changes in the drug due to any interactions
with the other additives present within the film matrix. The FTIR absorption bands of βCD are
summarized in Table 3 whilst those for plasticized DL MET are shown in Figure 8. The FTIR spectra
of DL MET films, showed the characteristic absorption bands of OME decreased in intensity which
could be due to dilution occurring from addition of βCD. There were no new bands observed in
the spectrum, which suggests that no new entities were generated from interaction between the film
components, as shown in Figure 8.
Table 3. The observed characteristic FTIR bands for pure cyclodextrin (CD).
Pure Materials Absorption Bands (cm−1) Bands Assignment
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Figure 8. FTIR spectra of drug loaded (DL) metolose (MET) films obtained from ethanolic gels
comprising 0.5% w/w polyethylene glycol (PEG 400) and OME:βCD:L-arg (1:1:1).
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3.3. Functional Characterization
3.3.1. Hydration (Swelling) Capacities
Plasticised DL MET films containing drug (OME) and stabilizer (L-arg) (ratio: 1:1), without βCD,
showed swelling index of 2630% in 20 min. After 20 min, the swelling remained constant or decreased
(data not shown) due to a loss of structural integrity. On the other hand, DL film containing βCD
in addition to L-arg showed swelling index value of 1197% after 20 min, which was significantly
lower (p < 0.05) compared to the above DL film with no βCD. This can be attributed to the interaction
between MET and βCD complex within the film matrix and therefore competing with water molecules
for bonding interactions with the polymer chains with a consequent decrease in hydration rate and
eventual swelling capacity. This is an interesting observation because it is generally known that CDs
are highly hydrophilic due to a high number of available OH groups.
3.3.2. Mucoadhesion
Figure 9 shows mucoadhesion data for DL MET film with and without βCD and the results
show statistically significant differences for PAF (stickiness) (p = 0.0284) and TWA (p = 0.0522)
whilst differences between their cohesiveness values were not significant (p = 0.2136). This could be
attributed to strong interaction (hydrogen bonding) between the polymer (MET) and the βCD both
of which contain large numbers of OH side groups, therefore reducing interaction with the model
mucosa surface.
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3.3.3. In Vitro Release of O E Using Franz-type Diffusion Cell
The release of drugs from matrix delivery systems such as films, can be controlled by diffusion
from the swollen matrix, by erosion of the polymer matrix or by a combination of both drug diffusion
and subsequent erosion of the matrix [40]. The dissolution profiles of the optimized O E loaded
films were observed over a period of two hours because, after 60 min, the percentage of O E release
remained constant. Furthermore, 2 h is the most realistic time frame for holding a formulation on the
buccal mucosa surface before complete hydration or possible dislodging due to chewing or tongue
movements [41]. Figure 10 shows the dissolution profile of the selected optimized DL ET film
containing OME:βCD:L-arg (1:1:1) in PBS (pH 6.8). The profile shows an initial linear release phase for
the first 60 min with the release reaching a maximum of 70% which did not change beyond 60 min.
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Figure 10. Drug dissolution profile of drug loaded (DL) metolose (MET) films prepared from ethanolic
(20% v/v EtOH) gel containing 0.5% w/w PEG 400 and OME:βCD:L-arg 1:1:1 ratio in PBS at pH 6.8
(mean ± SD,(n = 3)).
The mechani m of OME release was investigated by fitting the drug release data to various
kinetic models: zero order, firs order, Higuchi and Kor mey r–Peppas equations (coeffic ent, R2
values) [42]. The release kinetics of OME in PBS (pH 6.8) sho ed t at the drug release mec anism
followed Korsmeyer–Peppas model as the R2 value (0.9996) was the highest compared to other models.
Further, evaluation of the release exponents (n) provides additional information regarding the specific
molecular mechanism which controls drug release. OME release data from DL MET film containing
βCD gave an n value of 0.6 which was greater than 0.45, which indicates that the drug release followed
Fickian diffusion mechanism. This suggests that the OME was released through the hydrated (swollen)
polymer via diffusion combined with erosion controlled drug release.
3.4. Drug Stability
The chemical stability of OME within the ptimized MET DL film (OME:βCD:L-arg 1:1:1, PEG
400 (0.5% w/w), 20% v/v EtOH) was d termined by way of a short-term stability study foll wing
ICH guidelines. The films were placed in desiccators and wrapped with aluminium foil due to OME’s
known light sensitivity. The films were also wrapped in paraffin film to prevent moisture absorption
by MET and exposed to accelerated (40 ± 0.5 ◦C) and room temperature (ambient ± 0.5 ◦C) conditions
(ICH guidelines) for a period of 28 days (4 weeks). The results depicted in Figure 11 show that there
was a statistically significant difference (p < 0.05) between the per cent drug remaining within the film
kept in the oven at 40 ± 0.5 ◦C compared to the one stored under ambient conditions with the latter
remaining stable during the storage period. In the first 14 days, the drug content f OME in films kept
at 40 ± 0.5 ◦C was 63% compared o 99% at oom temperature and after 28 days the content of OME
was 59% at 40 ± 0.5 ◦C and 99% at room temperature. These observations suggest th t, when βCD
and L-arg are introduced into the film, it maintains the stability of OME at room temperature (ambient
± 0.5 ◦C) conditions but not under accelerated conditions of 40 ± 0.5 ◦C. The results give an indication
of the appropriate storage conditions for the formulated CD loaded films to maintain the stability of
OME possibly prolonging shelf life.
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temperature and oven temperature (40 ◦C) up to one month (mean ± SD, (n = 3)).
4. Conclusions
This study has shown the successful incorporation of both βCD and L-arg into OME loaded
mucoadhesive buccal films prepared from MET for potential treatment of GERD in children. From the
results obtained, it was shown that, when βCD was incorporated into the original optimized DL MET
film, it did not significantly affect the DSC and FTIR profiles and drug release characteristics. However,
there were changes observed in TGA, SEM, XRD, swelling and mucoadhesion properties. Furthermore,
the OME present in βCD loaded mucoadhesive films remained stable at room temperature over a
28-day period. This study has also shown that, although βCD can stabilize OME, the short to long
term stability of OME by βCD is also dependent on L-arg, which is known to increase pH to improve
the overall stability of the drug. Finally, OME was most stable at room temperature over the 28 days
compared to accelerated temperature of 40 ◦C, suggesting that the ideal environment to store the
βCD/L-arg stabilized mucoadhesive films will be under ambient temperature and humidity conditions.
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